TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemorrhoid bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of headaches frequency
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of clinical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone loss measured on X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain Visual Analog Score (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject self assessment of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comparison of safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Scatter Index (OSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort on Insertion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Comfort Before Removal
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of PET in detecting metastatic colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of change of cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adherence to Regional Guidelines for Immunization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: use of life-sustaining treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Unplanned hospitalisations or acute unscheduled care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Safety of the new device in its normal conditions of use
Endpoint domain: Adverse events/effects
Primary endpoint: Change in resting capillary blood flow velocity (CBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in peak CBV during reactive hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in time to peak CBV during reactive hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in transcutaneous oxygen pressure (TcPO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Subjective Dental Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Dysfunctional Dental Cognitions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional Impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rate of change in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Endpoint MMTT C_max for Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Between group TIR difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Insertion attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Keratoconus stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged methotrexate elimination time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma methylmalonic acid (MMA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intermediate metabolites in remnant muscular tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV risk reduction behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite measure of severity and number of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of migraine headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration vs time curve over the 24 hour dosing interval (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of diabetes-related clinical endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of death, MI, refractory ischemia, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in Neonatal Cardio-pulmonary outcome measure (N-COM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Stomach and Duodenum Visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUClast and Cmax of azithromycin and chloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Women Who Completed Advanced Directive
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oral layer structure as shown in OCT images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants For Whom the EEG Data Collection Was Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline Air Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Iron Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence With Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neuropsychological Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disability Assessment for Dementia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lawton and Brody Instrumental Activities of Daily Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Developed Positive Binding Antibodies (BAbs+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Change at 4 Weeks From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature change of relevant sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Loading Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Loading Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Loading Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Treatment Success on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ligament re-rupture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Durable Overall CSBM Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of otitis media episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in ability to do regular tasks of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in upper limb and hand impairment and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in reaching and grasping function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of Motion, Total Active Motion (TAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moberg Pickup Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Crohn's Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discussions regarding social media account
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Log Change (Reduction) in Skin Flora on the Inguinal Region at 10 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Log Change (Reduction) in Skin Flora on the Inguinal Region at 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Size of PDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass Correlation Coefficient between Lokomat score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HBV DNA < 29 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mouth Dryness Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aspartate aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gamma-glutamyltransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of Mid Regional Proadrenomedullin (MR-proADM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Pharmacokinetic (PK) Area Under the Concentration Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of PK Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary embolism prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in brain PET signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Regression of Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measured by change in the DLQI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-management abilities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Participation in daily and social activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Feeling of competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of cardiovascular disease and events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurologic status at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Follicle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Follicle diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Survivals
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients seropositive to HPV vaccine genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum walking distance in a 6-minute walk test at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum walking distance in a 6-minute walk test at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Financial Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal Analogue Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Cardiac Troponin I elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of DFO and deferasirox combination
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diameter of vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to Pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: sustained engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Rate of Adverse Cosmesis
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sweat chloride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-dimensional posture parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Lengthening of eyelashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Gingival Crevicular Fluid Interleukin - 6 (GCF IL-6) at 2 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: premobilization pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postmobilization pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's fear score before mobilization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: post-immunization geometric mean titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ctrough Serum Concentration of Ravulizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health and well-being (self-report)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flavor ratings of pediatric medicines and excipients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Palatability ratings of pediatric medicines and excipients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pathological changes in retinal artery occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Antitumor Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite of cardiac death, myocardial infarction, and stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of clinically driven target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retinal thickness after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity pattern during learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-Cog11 Score at 76 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in ADAS-Cog11 Score at 16 Weeks After Cessation of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in ADCS-ADL Inventory Score at 76 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADCS-ADL Inventory Score at 16 Weeks After Cessation of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of episode-free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of correct responses at a facial expression recognition task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Euclidian distance between predicted target and DBS lead contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological variables
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Lipid Panel Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) according to RECIST 1.1 by IRC
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Orally Administered YK-029A
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of atypical pathogens and mixed infections
Endpoint domain: Adverse events/effects
Primary endpoint: Occlusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: airway tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hyperreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Absolute Peripheral Blood Neutrophil (PBN) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Treatment for Unstable Angina/Non-STEMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Treatment for ST-elevation Myocardial Infarction (STEMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consultation and Relational Empathy Measure (CARE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Responsiveness to change of the QLQ-CML24
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under curve from zero time until the last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of the degree of cellulite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assessment of adipose tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of skin elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of SNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20 response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes